DARS antisense RNA 1 (DARS-AS1)

DARS antisense RNA 1 (DARS-AS1, also known as DARS1-AS1) is a cytoplasmic long noncoding RNA transcribed antisense to the DARS1 gene, with a well-documented role in promoting malignant behavior in multiple cancers, especially glioblastoma. It interacts with the RNA-binding protein YBX1 to stabilize target mRNAs (such as E2F1, CCND1, and FOXM1), which promotes cell cycle progression, proliferation, and homologous recombination-mediated DNA repair. DARS-AS1 is upregulated in several cancer types and its high expression is associated with poor prognosis, radioresistance, and reduced survival. Its key molecular functions include acting as a post-transcriptional regulator, scaffold molecule, and modulator of pathway signaling and mRNA methylation. Although no clinically approved drugs exist that directly target DARS-AS1, it is under investigation as a potential therapeutic target and biomarker in oncology[1][2][3].

Other names

DARS1-AS1DARS-AS1DARS1 antisense RNA 1

Regulation of mRNA stability by interacting with RNA-binding proteins (e.g., YBX1); Acting as scaffold/ceRNA to modulate signaling pathways (e.g., TGF-β/Smad3, cGMP-PKG); Regulation of gene expression through recruitment of methyltransferases (METTL3, METTL14)[3]